Prognostic Value of Myocardial Perfusion Scintigraphy with IQ∙SPECT Technology in Patients with Suspected or Known Coronary Artery Disease
International Journal of Cardiovascular Sciences · 10.04.2026 · 39
DOI: 10.36660/ijcs.20240202 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cardiovascular Sciences, erschienen am 10.04.2026. Verfasst von Maria Fernanda Rezende und 4 weiteren Autor:innen. Die Arbeit nennt 43 Literaturangaben.
Abstract (Originalsprache)
Background
IQ∙SPECT is a collimator design coupled with a cardio-centric acquisition orbit and specific reconstruction algorithm that increases camera efficiency. However, there is no prognostic data derived from IQ∙SPECT exams.
Objectives
To evaluate the prognostic value of IQ∙SPECT myocardial perfusion scintigraphy (MPS) in patients with suspected or known coronary artery disease (CAD).
Methods
The study population consisted of 734 consecutive patients with suspected or known CAD submitted to MPS with IQ∙SPECT. Adequate follow-up was obtained in 625 patients. We retrospectively analyzed imaging and clinical data. The follow-up was obtained for no less than 12 months after the MPS study. Statistical significance was taken at p < 0.05.
Results
Normal IQ∙SPECT compared to abnormal IQ∙SPECT had lower annualized incidence of hard events (0.2% and 1.1%, respectively, p = 0.02), late combined events (1.1% and 5.5%, respectively, p = 0.008), and revascularization (1% and 14%, respectively, p < 0.001). Left ventricular ejection fraction ≤ 45% was found to be the only clinical predictor of hard events (p < 0.0003, confidence interval [CI] = 5.25 to 129.02). However, for combined events, abnormal MPS (p < 0.0001, CI = 3.39 to 11.13, hazard ratio [HR] = 6.14) and dyspnea/fatigue (p = 0.013, CI = 1.28 to 8.4, HR = 3.3) obtained statistical significance. In contrast, ischemic burden ≥ 5% (p < 0.0001, HR = 30.3) was the most relevant parameter for revascularization, followed by thoracic pain (p = 0.002, HR = 2.4).
Conclusion
Our study demonstrates that IQ SPECT MPS has significant prognostic capabilities with very low risk of adverse events in patients with normal findings.
Zitieren
APA
Rezende, M. F., Yahiro, D. S., Fernandes, F. D. A., Azevedo, J., & Mesquita, C. T. (2026). Prognostic Value of Myocardial Perfusion Scintigraphy with IQ∙SPECT Technology in Patients with Suspected or Known Coronary Artery Disease. International Journal of Cardiovascular Sciences, 39. https://doi.org/10.36660/ijcs.20240202
Vancouver
Rezende MF, Yahiro DS, Fernandes FDA, Azevedo J, Mesquita CT. Prognostic Value of Myocardial Perfusion Scintigraphy with IQ∙SPECT Technology in Patients with Suspected or Known Coronary Artery Disease. International Journal of Cardiovascular Sciences. 2026;39. doi:10.36660/ijcs.20240202
BibTeX
@article{Rezende2026,
author = {Rezende, Maria Fernanda and Yahiro, Davi Shunji and Fernandes, Fernando de Amorim and Azevedo, Jader and Mesquita, Claudio Tinoco},
title = {Prognostic Value of Myocardial Perfusion Scintigraphy with IQ∙SPECT Technology in Patients with Suspected or Known Coronary Artery Disease},
journal = {International Journal of Cardiovascular Sciences},
year = {2026},
volume = {39},
doi = {10.36660/ijcs.20240202}
}
EUVIMED